Taneja 1965.

Methods	Randomized controlled trial Generation of allocation sequence: not stated Blinding: double blind Completeness: not assessable Surveillance: through participant making a postal, telephone, or clinic notification
Participants	Number: 51,135 persons of all ages and both sexes Previous vaccination status not explicitly given, but it is stated that "previous anti‐cholera vaccination, as usually practiced in an endemic zone" might have influenced the results
Interventions	Injected cholera vaccine: Classical bivalent (Ogawa + Inaba) Phenol‐killed whole cell (Vaccine Lab, W Bengal) Phenol‐killed whole cell (India) Formol‐killed freeze‐dried whole cell (Walter Reed) Formol‐killed whole cell (Haffkine Inst, Bombay) Vaccines made in India contained 8 x 109/dose Placebo: TAB (CRI) Route: injected Dose: 1 dose; 0.2 mL for ages 2 to 4 years; 0.4 mL for ages 5 to 8 years; 0.6 mL for ages 9 to 12 years; 0.8 mL for ages 13 to 15 years; 1 mL for ages > 15 years
Outcomes	Cholera cases Adverse effects within 24 hours
Location	India: Calcutta
Notes	Length of follow up: 6 months after the last vaccination (vaccination occurred during 12 March to 30 June 1964) WRAIR vaccine (No 3) supply ran short; this group had only 7975 participants compared to 10,784‐10,789 in the other groups Results from all 4 vaccine groups (all of which are Classical bivalent killed whole cell) have been combined at present Rates of adverse effects are very different in the 2 publications

Al(OH)₃: aluminium hydroxide (alum).